These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29875244)

  • 1. HIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding.
    Nevot M; Jordan-Paiz A; Martrus G; Andrés C; García-Cehic D; Gregori J; Franco S; Quer J; Martinez MA
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
    Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
    J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the human immunodeficiency virus type 1 protease: effects on viral replication capacity and protease robustness.
    Capel E; Martrus G; Parera M; Clotet B; Martínez MA
    J Gen Virol; 2012 Dec; 93(Pt 12):2625-2634. PubMed ID: 22933665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Lethality and Loss of Env Protein Expression Induced by Single Synonymous Substitutions in the Virus Genome Intronic-Splicing Silencer.
    Jordan-Paiz A; Nevot M; Lamkiewicz K; Lataretu M; Franco S; Marz M; Martinez MA
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of Human Respiratory Viruses by Synonymous Genome Recoding.
    Le Nouën C; Collins PL; Buchholz UJ
    Front Immunol; 2019; 10():1250. PubMed ID: 31231383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.
    Aoki M; Das D; Hayashi H; Aoki-Ogata H; Takamatsu Y; Ghosh AK; Mitsuya H
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in codon-pair bias of human immunodeficiency virus type 1 have profound effects on virus replication in cell culture.
    Martrus G; Nevot M; Andres C; Clotet B; Martinez MA
    Retrovirology; 2013 Jul; 10():78. PubMed ID: 23885919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.
    Lin YC; Happer M; Elder JH
    J Virol; 2013 Aug; 87(15):8524-34. PubMed ID: 23720716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness.
    Brann TW; Dewar RL; Jiang MK; Shah A; Nagashima K; Metcalf JA; Falloon J; Lane HC; Imamichi T
    J Virol; 2006 Jun; 80(12):6136-45. PubMed ID: 16731952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
    Koh Y; Aoki M; Danish ML; Aoki-Ogata H; Amano M; Das D; Shafer RW; Ghosh AK; Mitsuya H
    J Virol; 2011 Oct; 85(19):10079-89. PubMed ID: 21813613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
    Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
    J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.
    Su CT; Ling WL; Lua WH; Haw YX; Gan SK
    BMC Bioinformatics; 2016 Dec; 17(Suppl 19):500. PubMed ID: 28155724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.